Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1980 2
1983 2
1984 1
1985 1
1986 3
1987 2
1988 2
1989 2
1990 8
1991 4
1992 3
1993 4
1994 2
1995 3
1996 5
1997 6
1998 1
1999 3
2000 1
2001 6
2002 3
2003 3
2005 2
2006 1
2007 2
2008 3
2012 1
2013 1
2014 2
2015 3
2017 2
2018 2
2019 1
2020 1
2021 2
2023 2
2024 1
2025 3
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Systematic Review and Meta-Analyses Assessment of the Clinical Efficacy of Bismuth Subsalicylate for Prevention and Treatment of Infectious Diarrhea.
Brum JM, Gibb RD, Ramsey DL, Balan G, Yacyshyn BR. Brum JM, et al. Dig Dis Sci. 2021 Jul;66(7):2323-2335. doi: 10.1007/s10620-020-06509-7. Epub 2020 Aug 8. Dig Dis Sci. 2021. PMID: 32772204 Free PMC article.
In addition, short-term (48 h) medication with bismuth subsalicylate is known to be effective against infectious gastroenteritis such as travelers' diarrhea. AIMS: Previous studies have documented the bacteriostatic/bactericidal effects of bismuth subsalic …
In addition, short-term (48 h) medication with bismuth subsalicylate is known to be effective against infectious gastroenterit …
Bismuth subsalicylate therapy of viral gastroenteritis.
Steinhoff MC, Douglas RG Jr, Greenberg HB, Callahan DR. Steinhoff MC, et al. Gastroenterology. 1980 Jun;78(6):1495-9. Gastroenterology. 1980. PMID: 7372069 Clinical Trial.
The therapeutic efficacy of bismuth subsalicylate was examined in a randomized double-blind fashion in 59 volunteers who were inoculated with Norwalk agent. ...
The therapeutic efficacy of bismuth subsalicylate was examined in a randomized double-blind fashion in 59 volunteers who were …
Efficacy of bismuth subsalicylate on the prevention of travellers' diarrhoea, 2018-2023.
Angelo KM, Salah Z, Rogova M, Plumb ID, Walker AT, Prentice-Mott G, Waraich C, Kim S, Ryan E, LaRocque RC, Oliver E, Heitzinger K, Perry-Dow KA, Connor BA. Angelo KM, et al. J Travel Med. 2025 Oct 1;32(6):taaf047. doi: 10.1093/jtm/taaf047. J Travel Med. 2025. PMID: 40439228 Free PMC article. Clinical Trial.
BACKGROUND: Travellers' diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for the treatment of TD. BSS is also used off-label for the prevention of TD, based on studies from the 1980s indicating TD protection; however …
BACKGROUND: Travellers' diarrhoea (TD) is the most common travel-related illness. Bismuth subsalicylate (BSS) is indicated for …
Bismuth subsalicylate in the treatment of H2 blocker resistant duodenal ulcers: role of Helicobacter pylori.
Wagner S, Gebel M, Haruma K, Bär W, Lange P, Freise J, Gladziwa U, Schmidt FW. Wagner S, et al. Gut. 1992 Feb;33(2):179-83. doi: 10.1136/gut.33.2.179. Gut. 1992. PMID: 1347278 Free PMC article. Clinical Trial.
Cumulative ulcer healing rates after four and eight weeks respectively were as follows: bismuth subsalicylate 74% (14/19) and 95% (18/19), ranitidine 40% (8/20) and 65% (13/20), bismuth subsalicylate plus ranitidine 80% (16/20) and 95% (19/20). ...It m …
Cumulative ulcer healing rates after four and eight weeks respectively were as follows: bismuth subsalicylate 74% (14/19) and …
Effect of Bismuth Subsalicylate on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral Delayed-release Dimethyl Fumarate: PREVENT, a Randomized, Multicenter, Double-blind, Placebo-controlled Study.
Koulinska I, Riester K, Chalkias S, Edwards MR. Koulinska I, et al. Clin Ther. 2018 Dec;40(12):2021-2030.e1. doi: 10.1016/j.clinthera.2018.10.013. Epub 2018 Nov 15. Clin Ther. 2018. PMID: 30447891 Clinical Trial.
Bismuth subsalicylate 524 mg or placebo were administered 30 min before DMF (weeks 1-4). ...FINDINGS: A total of 175 participants were enrolled (placebo, n = 87; bismuth subsalicylate, n = 88), and 17 discontinued treatment (placebo, n = 8; bismuth …
Bismuth subsalicylate 524 mg or placebo were administered 30 min before DMF (weeks 1-4). ...FINDINGS: A total of 175 participa …
Bismuth subsalicylate in the treatment of acute diarrhea in children: a clinical study.
Soriano-Brücher H, Avendaño P, O'Ryan M, Braun SD, Manhart MD, Balm TK, Soriano HA. Soriano-Brücher H, et al. Pediatrics. 1991 Jan;87(1):18-27. Pediatrics. 1991. PMID: 1984613 Clinical Trial.
Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration therapy in 123 children, aged 4 to 28 months, hospitalized with acute diarrhea. ...Bismuth subsalicylate was well tolerated wit …
Bismuth subsalicylate (BSS) and placebo were evaluated in a double-blind, placebo-controlled study as adjunct to rehydration t …
A controlled trial of bismuth subsalicylate in infants with acute watery diarrheal disease.
Figueroa-Quintanilla D, Salazar-Lindo E, Sack RB, León-Barúa R, Sarabia-Arce S, Campos-Sánchez M, Eyzaguirre-Maccan E. Figueroa-Quintanilla D, et al. N Engl J Med. 1993 Jun 10;328(23):1653-8. doi: 10.1056/NEJM199306103282301. N Engl J Med. 1993. PMID: 8487823 Free article. Clinical Trial.
BACKGROUND: Bismuth subsalicylate is a common constituent of over-the-counter medications for diarrhea. ...No adverse reactions were seen. CONCLUSIONS: Treatment with bismuth subsalicylate decreases the duration of diarrhea and is a safe and effective …
BACKGROUND: Bismuth subsalicylate is a common constituent of over-the-counter medications for diarrhea. ...No adverse reaction …
Evaluation of bismuth subsalicylate in relieving symptoms of indigestion.
Hailey FJ, Newsom JH. Hailey FJ, et al. Arch Intern Med. 1984 Feb;144(2):269-72. Arch Intern Med. 1984. PMID: 6365007 Clinical Trial.
The efficacy of bismuth subsalicylate in relieving the symptoms of indigestion was evaluated in a randomized, placebo-controlled, double-blind, cross-over study in 48 adults. ...Overall relief was achieved faster and in a higher proportion of cases in bismuth …
The efficacy of bismuth subsalicylate in relieving the symptoms of indigestion was evaluated in a randomized, placebo-controll …
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).
Tungtrongchitr N, Bongkotvirawan P, Ratana-Amornpin S, Siramolpiwat S, Eiamsitrakoon T, Gamnarai P, Wongcha-Um A, Yamaoka Y, Pawa KK, Vilaichone RK. Tungtrongchitr N, et al. Sci Rep. 2024 Apr 18;14(1):8986. doi: 10.1038/s41598-024-59621-3. Sci Rep. 2024. PMID: 38637591 Free PMC article. Clinical Trial.
Potassium-competitive acid blockers (P-CABs) provide potent acid inhibition, yet studies on P-CAB-based quadruple therapy for H. pylori eradication are limited. We theorized that integrating bismuth subsalicylate into a quadruple therapy regimen could enhance eradic …
Potassium-competitive acid blockers (P-CABs) provide potent acid inhibition, yet studies on P-CAB-based quadruple therapy for H. pylori erad …
Bismuth subsalicylate in the treatment of gastritis due to Campylobacter pylori.
McNulty CA. McNulty CA. Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S94-8. doi: 10.1093/clinids/12.supplement_1.s94. Rev Infect Dis. 1990. PMID: 2406863 Clinical Trial.
Fifty patients completed an investigator-blind trial comparing bismuth subsalicylate, erythromycin ethylsuccinate, and placebo matched to the bismuth salt in the treatment of gastritis associated with Campylobacter pylori. ...
Fifty patients completed an investigator-blind trial comparing bismuth subsalicylate, erythromycin ethylsuccinate, and placebo …
96 results